Vaping inflames the brain

Innovation
Jul.05.2022
Perhaps it is not the healthier option we perceive it to be...

Rates of eCigarette and vaping product consumption have risen dramatically in recent years. In the UK over just the 5 year period from 2012 to 2017 it climbed by several hundred percent. Many users are former smokers who regard vaping as a healthier option and have switched for that reason. But there’s also a - for the moment small but - growing cohort of “never smokers” who vape because it’s perceived to be low risk. Could it be though that, in the same way that it took decades of following up smoking doctors before Richard Doll could categorically say that smoking causes health harms, vaping - being a relatively new phenomenon - just doesn’t have the data yet for us to know what the health risks are? This is very much the view of UCSD’s Laura Crotty-Alexander…

 

Laura - In terms of whether the e-cigarette aerosol mixture is safer than conventional tobacco smoke, it looks like it is going to have fewer health effects, but it will have its own set of health effects.

 

Chris - Which could be different and remote and, in fact, manifest in a different part of the body, presumably, if they're different chemicals then what's in cigarettes.

 

Laura - Absolutely. Cigarette smoke contains about 7,000 chemicals and that use of cigarettes leads to damage across the body. Everywhere from your lips, where it first makes contact, all the way down to the GI tract and out to the skin and to the brain. And what we sought to find was whether e-cigarette aerosols could also impact all these different organs across the body.

 

Chris - How did you do it?

 

Laura - We used a mouse model. So we have this special setup where we take the mice and we put them in a little pie-shaped wedge container where they can move around. And then we use e-cigarettes that we have bought on regular websites and we give them a puff of e-cigarette aerosol and then regular air. And we have them breathe that in for 30 minutes, three times a day.

 

Chris - And is the mouse dose equivalent to what a human consuming these products would get? Or are the mice getting a much bigger impact and a bigger dose? Because obviously a human breath would be massive for a mouse.

 

Laura - We do try our best to design these mouse models to mimic human use, which is why we expose the mice multiple times a day, because a lot of humans use e-cigarettes throughout the day. And when we take one puff that's more human sized, we actually put it into a large chamber where it diffuses. So 16 mice are breathing in that aerosol.

 

Chris - And how do you then marry up what that intake is doing in different parts of the body?

 

Laura - We actually harvest the mice and then we take all the different body parts. And we look at them using special tools that look at gene expression or levels of protein. And we actually even look at organ function. And so we use these different measures to try and determine whether inhaling these e-cigarette aerosols over months leads to changes in these organs.

 

Chris - And what crops up when you do this? Do you see systemic effects?

 

Laura - Yes. So I was very surprised that we found profound changes in the brain in particular of these mice that inhaled Juul mint and Juul mango, which are two flavors that were very popular at the time we started this study. And both of those aerosols led to inflammation in the brain, which is shocking because the brain is a protected compartment. So it was very worrisome that inhaling the e-cigarette aerosols for just a month led to very impressive levels of inflammation in a part of the brain that controls mood and behaviour and memory.

 

Chris - Are you saying that it's specifically the flavours that are doing that? So this is an effect beyond the addictive qualities of the nicotine and so on?

 

Laura - In the brain, the fact that we saw similar changes in both flavours indicated more that it was the nicotine and the other substances at the core of these e-liquids that were driving the changes. But, for example, in the heart, we found that the mint flavour really changed and drove inflammation, whereas the mango flavour did not. And so that comparison helped us to understand that maybe the heart effects are maybe particularly driven by the mint flavour and not the nicotine in other components.

 

Chris - We'll come on in a second to what the impact of that might be, but just considering for a minute the fact you've got this effect - how does it compare in scale with if the mice were just (if mice could) smoking normal cigarettes?

 

Laura - If I were to look back at the historic data, I would say that the neurologic effects are of a scale that appears to be either equal to, or greater than what is seen in conventional tobacco. And that the effects are different.

 

Chris - We believe that chronic inflammation might be linked to at least the progression, if not in some cases the cause, of certain neurodegenerative conditions and probably also degeneration in other organs. So do you think then that this is indicative of the fact that people doing this could be speeding up the aging process of their brain? They're effectively bringing forward the age at which they may well succumb to degenerative conditions of the nervous system?

 

Laura - I absolutely agree that that is a concern. And in addition, the changes in these parts of the brain suggest that people who are using e-cigarettes may have more anxiety and depression and might have sort of permanent changes to their behaviour patterns.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10